An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
Latest Information Update: 12 Aug 2024
At a glance
- Drugs NNZ 2591 (Primary)
- Indications Pitt-Hopkins syndrome
- Focus Adverse reactions; Pharmacokinetics
- Acronyms PTHS-001
- Sponsors Neuren Pharmaceuticals
- 08 Aug 2024 Status changed from active, no longer recruiting to completed.
- 27 May 2024 Results published in the Neuren Pharmaceuticals Media Release
- 05 Dec 2023 According to a Neuren Pharmaceuticals media release, top-line results from the trial are expected to be available in Q2 2024.